| Code | CSB-RA020978MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Crizanlizumab-TMCA, targeting SELP (P-selectin, also known as CD62P). P-selectin is a cell adhesion molecule expressed on activated endothelial cells and platelets that mediates the initial capture and rolling of leukocytes during inflammation. By binding to its ligand PSGL-1 on leukocytes, P-selectin plays a critical role in multicellular adhesive interactions that contribute to vaso-occlusion, a pathological process central to sickle cell disease. Elevated P-selectin expression is also implicated in various thrombotic and inflammatory conditions, including acute coronary syndromes, stroke, and cancer metastasis.
Crizanlizumab-TMCA is a humanized IgG2 kappa monoclonal antibody that binds to P-selectin and blocks its interaction with PSGL-1, thereby reducing cell adhesion events. This biosimilar provides researchers with a valuable tool for investigating P-selectin-mediated pathophysiology, studying vaso-occlusive mechanisms in hematological disorders, exploring endothelial-leukocyte interactions, and evaluating therapeutic strategies targeting adhesion molecules in inflammatory and thrombotic disease models.
There are currently no reviews for this product.